Xaira Therapeutics

Xaira Therapeutics

Biotechnology company focused on drug discovery

About Xaira Therapeutics

Simplify's Rating
Why Xaira Therapeutics is rated
A+
Rated B on Competitive Edge
Rated A+ on Growth Potential
Rated A+ on Differentiation

Industries

AI & Machine Learning

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$1B

Headquarters

Brisbane, California

Founded

2023

Overview

Xaira Therapeutics focuses on improving drug discovery and development through the use of artificial intelligence. The company employs machine learning techniques to analyze biological data, which helps in understanding the underlying mechanisms of diseases. By generating extensive data and developing new models, Xaira aims to create effective therapeutic products. What sets Xaira apart from its competitors is its integrated approach that combines advanced AI research, data generation, and product development under one roof. The goal of Xaira Therapeutics is to transform the way diseases are treated by making the drug development process more efficient and effective.

Simplify Jobs

Simplify's Take

What believers are saying

  • Xaira raised over $1 billion in funding, ensuring strong financial backing.
  • Expansion into San Francisco enhances access to biotech talent and collaboration.
  • AI-driven platforms optimize clinical trial designs, reducing time and cost.

What critics are saying

  • Competition from Isomorphic Lab with $600 million funding could challenge Xaira.
  • Rapid expansion into large San Francisco space may strain resources.
  • Multiple new executive appointments could lead to strategic misalignments.

What makes Xaira Therapeutics unique

  • Xaira integrates AI with molecular design for innovative drug discovery.
  • The company leverages insights from functional genomics and proteomics for new medicines.
  • Xaira collaborates with top researchers from the Institute for Protein Design.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1000M

Above

Industry Average

Funded Over

1 Rounds

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Benefits

Flexible Work Hours

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

↑ 4%

1 year growth

↑ 3%

2 year growth

↓ -1%
Xenoss
May 30th, 2025
Buils an innovative AI platform for drug discovery

Isomorphic Lab secured a record-breaking $600 million Series A in March 2025, and Xaira Therapeutics raised $200 million in 2024.

Aitech365
Apr 4th, 2025
Xaira Therapeutics Appoints Bo Wang as SVP, Head of AI

Xaira Therapeutics announced the appointment of Dr. Bo Wang as SVP and Head of Biomedical AI.

Intelligence360
Jan 6th, 2025
Xaira Therapeutics To Expand Into 73,075 Square Feet Of Space In San Francisco California.

Xaira Therapeutics to expand into 73,075 square feet of space in San Francisco California. Xaira Therapeutics to expand into 73,075 square feet of space in San Francisco California.San Francisco, California — According to state and local development sources, Xaira Therapeutics plans to build out 73,075 square feet of new space in San Francisco. The company plans to occupy the new space in San Francisco, on or about July 1, 2025. According to the company website Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.To learn more about Xaira Therapeutics, visit http://xaira.com/Company Contact:Uplaksh Kumar, Chief Operating [email protected]: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

Business Wire
Dec 11th, 2024
Xaira Therapeutics Announces the Appointment of Dr. Paulo Fontoura as Chief Medical Officer and Dr. Hetu Kamisetty as Chief Technology Officer

Xaira Therapeutics announces the appointment of Dr. Paulo Fontoura as Chief Medical Officer and Dr. Hetu Kamisetty as chief technology officer.

TechCrunch
Oct 26th, 2024
VC megadeals are booming - and AI is surprisingly not the top category

Xaira launched in April with a massive $1 billion round led by ARCH Venture Partners and Foresite Labs (both known for biotech), but with classic Silicon Valley VCs in the round, too, like NEA, Sequoia Capital, Lightspeed Venture Partners, SV Angel, and others.

Recently Posted Jobs

Sign up to get curated job recommendations

Xaira Therapeutics is Hiring for 20 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Xaira Therapeutics's jobs every few hours, so check again soon! Browse all jobs →